# US 2013/0156699 A1 · Radiolabeled compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156699 A1
- Document ID: US20130156699A1
- Status: Published application
- Kind: A1
- Application number: 13/668,975
- Filed: 2012-11-05
- Published: 2013-06-20
- Earliest claimed: 2010-05-05
- Assignees: The Trustees of Columbia University in the City of New York
- Inventors: Joseph John MANN; J.S. Dileep KUMAR
- Web page: https://patentgrep.com/patent/US20130156699A1

## CPC

- C07D 253/075: Two hetero atoms, in positions 3 and 5
- A61K 51/0461: {having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K51/0472)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C07B 59/002: {Heterocyclic compounds}
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to Radiolabeled Compounds labeled with fluorine, bromine, iodine, carbon, or tritium isotopes and methods of use thereof for treating or preventing a psychiatric disorder in a subject, for stabilizing the mood of a subject having a mood disorder, or as imaging agents for a serotonin receptor. Compositions comprising an imaging-effective amount of a Radiolabeled Compound are also disclosed.

## Claims

### Claim 1

A compound having the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
r and s are each independently an integer ranging from 0 to 3;
R1 is —C1-C6 alkyl,
R2 is —H, and
R3 is -aryl, -heteroaryl or -napththyl, each of which is substituted with 75Br, 76Br, 120I, 123I, 124I, 125I, 131I, or —OC3HH2.

### Claim 2 (depends on 1)

The compound of claim 1, the compound having the formula
or pharmaceutically acceptable salts thereof, wherein Y is —CH— or —N— and Rr is —OC3HH2, 75Br, 76Br, 120I, 123I, 124I, 125I, or 131I.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 is methyl.

### Claim 4 (depends on 1)

The compound of claim 1, having the formula:
or a pharmaceutically acceptable salt thereof, wherein Br is 75Br or 76Br and I is 120I, 123I, 124I, 125I or 131I.

### Claim 5

A compound having the formula:
or a pharmaceutically acceptable salts thereof,
wherein:
R1 is —C1-C6 alkyl,
W is a bond or a carbonyl; and
R3 is -aryl or -heteroaryl, each of which are optionally substituted with 18F, or —O—C1-C4alkyl, wherein —O—C1-C4alkyl is further substituted with 18F; and wherein said aryl or heteroaryl are optionally substituted with —CN.

### Claim 6 (depends on 5)

The compound of claim 5, wherein W is a bond and R3 is -aryl substituted with —O—CH2—18F, —O—CH2—CH2—18F, or —O—CH2—CH2—CH2—18F.

### Claim 7 (depends on 5)

The compound of claim 5, wherein W is a bond and R3 is phenyl or naphthyl, each of which are substituted with —O—CH2—18F, —O—CH2—CH2—18F, or —O—CH2—CH2—CH2—18F.

### Claim 8 (depends on 5)

The compound of claim 5 having the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1, 5)

A composition comprising a physiologically acceptable salt and the compound of claims 1 or 5, or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1, 5)

A composition comprising a therapeutically effective amount of a compound of claims 1 or 5, or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier or vehicle.

### Claim 11 (depends on 1, 5)

A composition comprising an imaging-effective amount of a compound of claims 1 or 5, or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier or vehicle.

### Claim 12 (depends on 1, 5)

A method for imaging one or more 5-HT1A receptors in a subject in vivo, the method comprising:
(a) administering to the subject an imaging-effective amount of the compound of claim 1 or 5, or a pharmaceutically acceptable salt thereof; and
(b) detecting the radioactive emission of the compound or salt thereof administered to the subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein the radioactive emission is detected using positron-emission tomography.

### Claim 14 (depends on 12)

The method of claim 12, wherein the radioactive emission is detected in the brain of the subject.

### Claim 15 (depends on 12)

The method of claim 12, wherein the subject is known or suspected to have a neurological disorder.

### Claim 16 (depends on 15)

The method of claim 15, wherein the neurological disorder is an affective disorder, an anxiety disorder, an eating disorder, an addictive disorder, a sleep disorder, a disease associated with cognitive dysfunction, a neurodegenerative disease, such as stroke; a seizure disorder, a pain disorder; a panic disorder, a disorder of movement, or an obsessive-compulsive disorder.

### Claim 17 (depends on 16)

The method of claim 16, wherein the disease associated with cognitive dysfunction is Alzheimer's disease.

### Claim 18 (depends on 16)

The method of claim 16, wherein the neurodegenerative disease is stroke.

### Claim 19 (depends on 16)

The method of claim 16, wherein the disorder of movement is Parkinson's disease.

### Claim 20 (depends on 16)

The method of claim 16, wherein the seizure disorder is epilepsy.

### Claim 21 (depends on 16)

The method of claim 16, wherein the affective disorder is depression.

### Claim 22 (depends on 16)

The method of claim 16, wherein the compound selectively binds to the 5-HT1A receptor relative to other serotonin receptors.

### Claim 23 (depends on 1, 5)

A method for diagnosing or evaluating a psychiatric disorder or a neurological disorder in a subject, the method comprising administering to the subject an imaging effective amount of the compound of claim 1 or claim 5, or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the disorder is Alzheimer's disease.
